Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: mt-3724, citatuzumab bogatox, ataluren +2 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 145 | 0.91 |
| pathways Reactome | 22 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 16796
Sealed predictions
- RPS9 in dopamine neurons, braak+0.10 (p 0.790) → +0.06 (p 0.869)receipt 16803
Swarm cases
receipt 16803: RPS9 in dopamine neurons, braak
- power
- full sample -0.03 (p 0.922, n 18), 95% CI -0.49 to +0.45. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.02 (p 0.935, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.02 (p 0.935, n 18). could be the mix.
- skeptic
- leave-one-out range -0.18 to +0.08, sign flips 8; without severely affected donors -0.03 (p 0.922, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RPS9 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts